Nexus Biopharma, Inc. (NEXS) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
JLABS @ TMCX HOUSTON, TX 77021-2040 |
| State of Incorp. | |
| Fiscal Year End | February 28 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 2/28/2017 | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 0 | 0 | |||||
| Cash and cash equivalents | 0 | 0 | |||||
| Prepaid expense | 1 | 5 | ✕ | ||||
| Total current assets: | 1 | 5 | 0 | ||||
| Noncurrent Assets | |||||||
| Property, plant and equipment | 2 | ||||||
| Intangible assets, net (including goodwill) | 7 | ✕ | ✕ | ||||
| Intangible assets, net (excluding goodwill) | 7 | ||||||
| Total noncurrent assets: | 8 | ||||||
| TOTAL ASSETS: | 10 | 5 | 0 | ||||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities, including: | 836 | 26 | 16 | 22 | 10 | ||
| Accounts payable | 200 | 26 | 16 | 22 | 10 | ||
| Other undisclosed accounts payable and accrued liabilities | 636 | ||||||
| Debt | 293 | ||||||
| Due to related parties | 88 | 59 | |||||
| Other undisclosed current liabilities | 200 | 32 | 21 | 17 | |||
| Total current liabilities: | 1,416 | 85 | 49 | 42 | 27 | ||
| Noncurrent Liabilities | |||||||
| Long-term debt and lease obligation | 48 | ||||||
| Long-term debt, excluding current maturities | 48 | ||||||
| Total noncurrent liabilities: | 48 | ||||||
| Total liabilities: | 1,463 | 85 | 49 | 42 | 27 | ||
| Stockholders' equity | |||||||
| Stockholders' equity attributable to parent, including: | (1,454) | (85) | (44) | (42) | (27) | ||
| Common stock | 64 | ||||||
| Additional paid in capital | 1,776 | 42 | 42 | 42 | (86) | ||
| Accumulated deficit | (3,294) | (191) | (149) | (148) | (133) | ||
| Other undisclosed stockholders' equity attributable to parent | 64 | 64 | 64 | 191 | |||
| Total stockholders' equity: | (1,454) | (85) | (44) | (42) | (27) | ||
| TOTAL LIABILITIES AND EQUITY: | 10 | 5 | 0 | ||||
Income Statement (P&L) ($ in thousands) Annual | Quarterly
| 2/28/2017 | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|---|---|
| Gross profit: | (30) | |||||
| Operating expenses | (655) | (42) | (3) | (31) | (33) | |
| Operating loss: | (685) | (42) | (3) | (31) | (33) | |
| Interest and debt expense | (27) | |||||
| Net loss: | (685) | (69) | (3) | (31) | (33) | |
| Other undisclosed net income (loss) attributable to parent | (1) | 27 | 1 | 15 | 23 | |
| Net loss available to common stockholders, diluted: | (686) | (42) | (1) | (15) | (9) | |
Comprehensive Income ($ in thousands)Annual | Quarterly
| 2/28/2017 | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|---|---|
| Net loss: | (685) | (69) | (3) | (31) | (33) | |
| Comprehensive loss, net of tax, attributable to parent: | (685) | (69) | (3) | (31) | (33) | |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.